Form 4 for BOLD Boundless Bio, Inc.
Accepted 2024-04-02 00:00:00 ET · period of report 2024-04-02 · accession 0001415889-24-009885 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-04-02 | 2024-04-02 | BOLD | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% | C - Cnv Deriv | — | +556.2K | 189.9K | New | — |
| DM | 2024-04-02 | 2024-04-02 | BOLD | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% | C - Cnv Deriv | $0.00 | -10.85M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-02 | C | A | 366,300 | — | 556,233 | D | — | — | (F2) On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date. |
| 2 | Common | Common Stock | 2024-04-02 | C | A | 189,933 | — | 189,933 | D | — | — | (F1) On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. |
| 3 | Derivative | Series C Preferred Stock | 2024-04-02 | C | D | 7,142,857 | $0.00 | 0 | D | — · — to — | 366,300 Common Stock | (F2) On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date. |
| 4 | Derivative | Series B Preferred Stock | 2024-04-02 | C | D | 3,703,704 | $0.00 | 0 | D | — · — to — | 189,933 Common Stock | (F1) On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. |